NewGenIvf Competitors

Stocks . USA . 
Stock . NewGenIvf Group Limited
NIVF Stock   0.88  0.05  5.38%   
NewGenIvf Group competes with Scworx Corp, ZyVersa Therapeutics, Conduit Pharmaceuticals, INVO Fertility, and Envoy Medical; as well as few others. The company conducts business under Health Care Providers & Services sector and is part of Health Care industry. Analyzing NewGenIvf Group competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of NewGenIvf Group to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out NewGenIvf Group Correlation with its peers.

NewGenIvf Group vs Longevity Health Correlation

Very weak diversification

The correlation between NewGenIvf Group Limited and XAGE is 0.5 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding NewGenIvf Group Limited and XAGE in the same portfolio, assuming nothing else is changed.

Moving against NewGenIvf Stock

  0.64AHX Apiam Animal Health Earnings Call Next WeekPairCorr
  0.52EHAB EnhabitPairCorr
  0.52AMN AMN Healthcare Services Earnings Call Next WeekPairCorr
  0.44BKD Brookdale Senior LivingPairCorr
  0.43NPTH NeuPath HealthPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NewGenIvf Group's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.030.6211.16
Details
Intrinsic
Valuation
LowRealHigh
0.040.8411.38
Details

NewGenIvf Group Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between NewGenIvf Group and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of NewGenIvf and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of NewGenIvf Group does not affect the price movement of the other competitor.

High positive correlations

PTPI
+ 0.85
CDT
CDT
+ 0.84
WORX
PTPI
+ 0.84
WORX
XAGE
+ 0.66
IVF
COCH
+ 0.63
CDT
PETV
+ 0.63
CDT
  

High negative correlations

PETV
- 0.6
ZVSA
COCH
- 0.46
ZVSA
CDT
- 0.44
ZVSA
PTPI
- 0.41
ZVSA
ZVSA
- 0.4
WORX
CCM
- 0.3
PETV

Risk-Adjusted Indicators

There is a big difference between NewGenIvf Stock performing well and NewGenIvf Group Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze NewGenIvf Group's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
WORX  4.65 (0.76) 0.00 (0.65) 0.00 
 0.00 
 6.25 
(10.00)
 50.00 
HEPA  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ZVSA  6.62  0.77  0.08  0.59  6.01 
(13.54)
 15.38 
(11.76)
 86.14 
CDT  5.32 (1.17) 0.00 (0.39) 0.00 
 0.00 
 12.43 
(13.57)
 40.12 
IVF  10.38  0.66  0.00  0.01  0.00 
 0.00 
 12.22 
(16.50)
 218.36 
COCH  4.78  0.06  0.06  0.11  4.58 
(8.11)
 6.94 
(7.79)
 35.48 
PETV  3.68 (0.84) 0.00 (0.65) 0.00 
 0.00 
 7.48 
(9.77)
 32.58 
CCM  4.66 (0.52) 0.00 (0.45) 0.00 
 0.00 
 12.41 
(9.32)
 25.36 
PTPI  6.38 (1.18) 0.00 (0.38) 0.00 
 0.00 
 12.50 
(12.50)
 55.00 
XAGE  6.01 (0.50) 0.00 (1.13) 0.00 
 0.00 
 18.60 
(18.75)
 46.80 

NewGenIvf Group Competitive Analysis

The better you understand NewGenIvf Group competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, NewGenIvf Group's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across NewGenIvf Group's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
NIVF WORX HEPA ZVSA CDT IVF COCH PETV CCM PTPI
 5.38 
 0.88 
NewGenIvf
 5.56 
 0.19 
Scworx
 8.33 
 0.11 
Hepion
 25.00 
 0.20 
ZyVersa
 1.79 
 1.10 
Conduit
 0.90 
 1.10 
INVO
 69.23 
 0.66 
Envoy
 6.98 
 0.80 
PetVivo
 1.06 
 3.81 
Concord
 12.50 
 0.01 
Petros
Market Volatility
(90 Days Market Risk)
Out of control
Out of control
Very steady
Very risky
Abnormally volatile
Out of control
Dangerous
Abnormally volatile
Very risky
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Mild
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Low
Hazard
Moderate
High
Strong
Risky
Risky
High
Risky
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Hold
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Not Rated
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
N/A
0.27
8.77
N/A
N/A
N/A
N/A
4.15
0.71
3.1
Net Asset
3.58 M
6.35 M
1.61 M
20.6 M
4.19 M
46.45 M
11.54 M
9.34 M
6.73 B
10.64 M
Profit Margin
3.81
-1.4
N/A
N/A
N/A
N/A
N/A
N/A
-0.45
-2.8
EBITDA
24.26 K
227.4 K
(19.35 M)
(9.14 B)
(15.84 M)
(7.14 M)
(19.81 M)
(7.69 M)
(345.62 M)
(10.81 M)
Operating Margin
-1.96
-0.2
N/A
N/A
N/A
-1.5
-135.9
-6.81
-0.72
-2.41
Current Valuation
6.11 M
2.17 M
5.39 M
(1.51 M)
709.05 K
43.84 M
11.13 M
35.44 M
541.67 M
(1.42 M)
Price To Book
0.0305
0.48
2.11
0.21
0.62
5.97
4.22
8.68
3.0
0.45
Retained Earnings
(985.99 K)
(30.98 M)
(237.82 M)
(112.63 M)
(29.1 M)
(67.16 M)
(284.73 M)
(91.2 M)
(4.37 B)
(113.21 M)
Current Asset
N/A
1.79 M
4.82 M
N/A
N/A
N/A
N/A
37 K
1.51 B
N/A
Beta
-0.045
2.15
1.9
0.81
1.77
N/A
2.09
1.47
-1.21
2.2
Number Of Employees
76
7
12
7
6
33
42
24
595
18
Shares Outstanding
982.69 K
15.83 M
10.93 M
8.1 M
2.3 M
2.16 M
28.93 M
33.58 M
2.82 M
2.14 M
Cash Flow From Operations
(8.26 M)
(1.08 M)
(18.22 M)
(7.56 M)
(9.68 M)
(2.97 M)
(17.95 M)
(5.32 M)
(397.75 M)
(2.6 M)
Total Debt
3.03 M
47.03 K
2.9 M
12.08 M
7.46 M
9.9 M
19.66 M
2.9 M
3.93 B
7.39 M
Return On Equity
1.61
-0.74
-4.87
-1.13
N/A
N/A
N/A
-4.14
-0.29
-5.71
Return On Asset
-0.23
-0.1
-1.23
-0.46
-2.07
N/A
-1.45
-1.15
-0.0448
-0.29
Number Of Shares Shorted
64.2 K
82.27 K
448.18 K
359.25 K
277.73 K
354.43 K
430.61 K
129.1 K
1.3 K
12.35 M
Book Value Per Share
204.69
0.52
-25.57
-1.45
3.35
-108.71
-0.32
0.13
-74.05
-17.73
Current Liabilities
N/A
3.69 M
1.81 M
N/A
N/A
N/A
N/A
1.6 M
1.51 B
N/A
Total Asset
3.58 M
6.35 M
1.61 M
20.6 M
4.19 M
46.45 M
11.54 M
9.34 M
6.73 B
10.64 M
Short Ratio
0.08
0.11
0.05
0.25
1.21
0.07
2.66
4.45
0.12
0.17
Target Price
225.0
N/A
30.0
20.0
N/A
N/A
7.0
7.0
1.2
1.0
Debt To Equity
N/A
0.068
0.001
N/A
N/A
N/A
N/A
0.074
1.25
0.31
Shares Owned By Institutions
0.15
7.03
8.99
5.14
1.02
5.27
7.16
N/A
0.036
6.79
Market Capitalization
897.35 K
2.83 M
3.47 M
1.62 M
2.67 M
5.51 M
13.6 M
36.27 M
16.54 M
265.45 K
Price To Earning
N/A
-72.5
-3.01
N/A
N/A
N/A
N/A
-5.76
-3.9
N/A
Price To Sales
0.2
1.02
N/A
N/A
N/A
0.84
65.4
25.74
0.0452
0.0519
Net Income
(474.1 K)
(1.14 M)
(13.19 M)
(9.41 M)
(17.8 M)
(9.1 M)
(22.45 M)
(8.4 M)
(652.08 M)
(14.32 M)
Earnings Per Share
4195.34
-0.85
-5367.5
-3.32
-179.34
-105.51
-1.37
-0.4
-5.4
-63.15
Shares Owned By Insiders
0.13
0.47
0.19
0.02
25.97
11.58
37.0
35.4
17.99
7.39
Revenue
5.43 M
2.99 M
N/A
N/A
922.22 M
6.53 M
225 K
1.13 M
383.96 M
5.11 M
Working Capital
452.39 K
(1.33 M)
(1.53 M)
(9.52 M)
(8.03 M)
(16.61 M)
1.85 M
1.29 M
(1.14 B)
(10.73 M)
Cash And Equivalents
N/A
23.49 K
59.15 M
N/A
N/A
N/A
N/A
4.38 M
157.39 M
13.3 M
Cash Per Share
N/A
N/A
0.78
N/A
N/A
N/A
N/A
0.44
1.72
0.64
Gross Profit
970.96 K
727.66 K
N/A
N/A
N/A
2.74 M
(612 K)
1.11 M
(41.85 M)
3.9 M
Day Typical Price
0.88
0.18
0.12
0.19
1.07
1.14
0.64
0.81
3.85
0.0075
Accumulation Distribution
15298.8
209147.0
0.21
0.2
3909.75
97095.31
14.6 M
0.093
0.0794
19674.42
Market Facilitation Index
N/A
N/A
0.03
0.04
0.0
N/A
N/A
0.08
0.32
N/A
Daily Balance Of Power
(0.71)
0.5
(0.33)
1.0
(0.25)
(0.06)
0.54
(0.75)
0.125
(0.62)
Period Momentum Indicator
(0.05)
0.01
(0.01)
0.04
(0.02)
(0.01)
0.27
(0.06)
0.04
(0)
Rate Of Daily Change
0.95
1.06
0.92
1.25
0.98
0.99
1.69
0.93
1.01
0.88
Day Median Price
0.89
0.18
0.13
0.18
1.06
1.16
0.63
0.82
3.87
0.0078
Price Action Indicator
(0.03)
0.015
(0.02)
0.04
0.03
(0.07)
0.17
(0.05)
(0.04)
(0)
Coefficient Of Variation
(438.38)
(1,078)
N/A
1269.93
(798.73)
(27,859)
2411.06
(713.35)
(1,430)
(1,083)
Mean Deviation
7.3
4.65
N/A
6.62
5.32
10.38
4.78
3.68
4.66
6.38
Jensen Alpha
(2.44)
(0.76)
N/A
0.7665
(1.17)
0.664
0.0565
(0.84)
(0.52)
(1.18)
Total Risk Alpha
(3.66)
(1.49)
N/A
(0.47)
(1.82)
(3.18)
(0.81)
(1.34)
(1.15)
(2.15)
Sortino Ratio
N/A
N/A
N/A
0.0834
N/A
N/A
0.0615
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
96.03
N/A
N/A
29.23
N/A
N/A
N/A
Standard Deviation
10.54
7.02
N/A
11.69
7.44
26.12
10.52
5.17
6.06
10.17
Kurtosis
1.13
8.36
N/A
18.54
1.17
47.03
35.34
2.77
0.0134
2.93
Potential Upside
15.95
6.25
N/A
15.38
12.43
12.22
6.94
7.48
12.41
12.5
Treynor Ratio
(7.85)
(0.65)
N/A
0.5911
(0.39)
0.0126
0.1077
(0.65)
(0.45)
(0.38)
Maximum Drawdown
53.65
50.0
N/A
86.14
40.12
218.36
35.48
32.58
25.36
55.0
Variance
111.18
49.31
N/A
136.62
55.29
682.02
110.59
26.74
36.75
103.35
Market Risk Adjusted Performance
(7.84)
(0.64)
N/A
0.6011
(0.38)
0.0226
0.1177
(0.64)
(0.44)
(0.37)
Risk Adjusted Performance
(0.17)
(0.06)
N/A
0.0717
(0.09)
0.0069
0.0421
(0.10)
(0.05)
(0.06)
Skewness
(0.06)
1.59
N/A
3.39
(0.06)
6.39
5.25
0.4985
0.4487
0.5845
Semi Deviation
N/A
N/A
N/A
6.01
N/A
N/A
4.58
N/A
N/A
N/A
Information Ratio
(0.24)
(0.11)
N/A
0.0699
(0.14)
(0.01)
0.0316
(0.16)
(0.09)
(0.10)
Value At Risk
(21.23)
(10.00)
N/A
(11.76)
(13.57)
(16.50)
(7.79)
(9.77)
(9.32)
(12.50)
Expected Short fall
N/A
N/A
N/A
(13.54)
N/A
N/A
(8.11)
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
9.8
N/A
N/A
5.41
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
36.16
N/A
N/A
20.94
N/A
N/A
N/A

NewGenIvf Group Competition Performance Charts

Five steps to successful analysis of NewGenIvf Group Competition

NewGenIvf Group's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by NewGenIvf Group in relation to its competition. NewGenIvf Group's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of NewGenIvf Group in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact NewGenIvf Group's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to NewGenIvf Group, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your NewGenIvf Group position

In addition to having NewGenIvf Group in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch
When determining whether NewGenIvf Group is a strong investment it is important to analyze NewGenIvf Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NewGenIvf Group's future performance. For an informed investment choice regarding NewGenIvf Stock, refer to the following important reports:
How To Invest In NewGenIvf
Details
Is NewGenIvf Stock a good investment?
Details
What is NewGenIvf Group's Net Worth?
Details
Top Sectors
View
Check out NewGenIvf Group Correlation with its peers.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Can Health Care Providers & Services industry sustain growth momentum? Does NewGenIvf have expansion opportunities? Factors like these will boost the valuation of NewGenIvf Group. Anticipated expansion of NewGenIvf directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating NewGenIvf Group demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding NewGenIvf Group requires distinguishing between market price and book value, where the latter reflects NewGenIvf's accounting equity. The concept of intrinsic value - what NewGenIvf Group's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push NewGenIvf Group's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between NewGenIvf Group's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NewGenIvf Group should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, NewGenIvf Group's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY